Pfizer to Acquire Arena for $6.7B, Expanding Immuno-Inflamma

Pfizer has agreed to acquire Arena Pharmaceuticals for approximately $6.7 billion, in a deal designed to expand the buyer’s immuno-inflammatory disease pipeline, led by Arena’s Phase II/II lead candidate etrasimod.

Related Keywords

Boston , Massachusetts , United States , San Diego , California , Switzerland , Bristol Myers Squibb Zeposia , Josephp Schwartz , Amitd Munshi , Mike Gladstone , Bristol Myers Squibb , Schwartz , Pfizer , Arena Pharmaceuticals , Pfizer Inflammation , Aristea Therapeutics , Park City ,